UPNEEQ
Peakoxymetazoline hydrochloride ophthalmic
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPNEEQ is an oxymetazoline hydrochloride ophthalmic solution approved in July 2020 for the treatment of acquired ptosis (drooping eyelid). It is a selective alpha-1 adrenergic receptor agonist that works topically on the eye to elevate the eyelid by stimulating Müller's muscle. This represents a novel non-surgical option for patients seeking eyelid elevation.
Peak13.2 years to LOE
UPNEEQ is in peak commercial phase post-launch, indicating stable team structure and ongoing commercial execution for specialty ophthalmology segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
UPNEEQ presents career opportunities in specialty ophthalmology commercialization during a peak commercial phase. Positions typically involve patient education, provider engagement, and market share defense in a focused therapeutic area with limited direct competition.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.